Study of Codivir in Patients With COVID-19

administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.

rapid test for the diagnosis of COVID-19 based on the detection of anti-SARS-CoV-2 in the blood.

blood collection for dosage of Anti SARS-CoV-2 antibodies.

detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.

complete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; fibrinogen, Pregnancy test for non-sterile women.

12-lead electrocardiogram with report.

evaluation by the principal investigator or assistant physician with a complete physical examination.

assessment of the participant by the NEWS-2 score.

assessment of the participant by the score of the World Health Organization.